Danielle Wallace1, Carla Casulo2. 1. James P. Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmwood Avenue Box 704, Rochester, NY, 14642, USA. 2. James P. Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmwood Avenue Box 704, Rochester, NY, 14642, USA. carla_casulo@urmc.rochester.edu.
Abstract
PURPOSE OF REVIEW: Follicular lymphoma is an indolent lymphoma which does not limit life expectancy in most patients; however, approximately 20% of patients will experience progression of disease within 24 months (POD24) of diagnosis and have inferior survival outcomes. To date, no clinical, genetic, or tumor microenvironment prediction models have been able to definitively predict which patients will experience POD24 which limits the ability to alter frontline management of patients suspected to be at high risk of early progression. Here, we review recent literature regarding novel prediction models and management recommendations for POD24 patients. RECENT FINDINGS: Recent studies have revealed novel clinicopathologic prediction models which may be closer to identifying patients at risk of POD24. In addition, several clinical trials utilizing novel therapies such as tazemetostat, obinutuzumab, PI3K inhibitors, and lenalidomide have been performed which help further guide treatment. Ongoing trials seek to identify the optimal management of these patients, and data from bispecific antibodies and CAR T cell therapies is forthcoming. With ongoing research efforts, hope remains that we are closer to being able to predict which patients will experience early progressing follicular lymphoma and have an improved management plan for those who do in order to improve survival outcomes.
PURPOSE OF REVIEW: Follicular lymphoma is an indolent lymphoma which does not limit life expectancy in most patients; however, approximately 20% of patients will experience progression of disease within 24 months (POD24) of diagnosis and have inferior survival outcomes. To date, no clinical, genetic, or tumor microenvironment prediction models have been able to definitively predict which patients will experience POD24 which limits the ability to alter frontline management of patients suspected to be at high risk of early progression. Here, we review recent literature regarding novel prediction models and management recommendations for POD24 patients. RECENT FINDINGS: Recent studies have revealed novel clinicopathologic prediction models which may be closer to identifying patients at risk of POD24. In addition, several clinical trials utilizing novel therapies such as tazemetostat, obinutuzumab, PI3K inhibitors, and lenalidomide have been performed which help further guide treatment. Ongoing trials seek to identify the optimal management of these patients, and data from bispecific antibodies and CAR T cell therapies is forthcoming. With ongoing research efforts, hope remains that we are closer to being able to predict which patients will experience early progressing follicular lymphoma and have an improved management plan for those who do in order to improve survival outcomes.
Authors: Ciara L Freeman; Robert Kridel; Alden A Moccia; Kerry J Savage; Diego R Villa; David W Scott; Alina S Gerrie; David Ferguson; Fergus Cafferty; Graham W Slack; Pedro Farinha; Brian Skinnider; Joseph M Connors; Laurie H Sehn Journal: Blood Date: 2019-07-12 Impact factor: 22.113
Authors: Vindi Jurinovic; Robert Kridel; Annette M Staiger; Monika Szczepanowski; Heike Horn; Martin H Dreyling; Andreas Rosenwald; German Ott; Wolfram Klapper; Andrew D Zelenetz; Paul M Barr; Jonathan W Friedberg; Stephen Ansell; Laurie H Sehn; Joseph M Connors; Randy D Gascoyne; Wolfgang Hiddemann; Michael Unterhalt; David M Weinstock; Oliver Weigert Journal: Blood Date: 2016-07-14 Impact factor: 22.113
Authors: Clara Sortais; Anne Lok; Benoit Tessoulin; Thomas Gastinne; Béatrice Mahé; Viviane Dubruille; Nicolas Blin; Cyrille Touzeau; Anne Moreau; Céline Bossard; Pierre Peterlin; Alice Garnier; Thierry Guillaume; Amandine Le Bourgeois; Patrice Chevallier; Philippe Moreau; Christophe Leux; Steven Le Gouill Journal: Ann Hematol Date: 2020-05-16 Impact factor: 3.673
Authors: Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg Journal: J Clin Oncol Date: 2015-06-29 Impact factor: 44.544
Authors: Matthew J Maurer; Emmanuel Bachy; Hervé Ghesquières; Stephen M Ansell; Grzegorz S Nowakowski; Carrie A Thompson; David J Inwards; Cristine Allmer; Catherine Chassagne-Clément; Emmanuelle Nicolas-Virelizier; Catherine Sebban; Laure Lebras; Clementine Sarkozy; William R Macon; Andrew L Feldman; Sergei I Syrbu; Alexandra Traverse-Glehan; Bertrand Coiffier; Susan L Slager; George J Weiner; Thomas E Witzig; Thomas M Habermann; Gilles Salles; James R Cerhan; Brian K Link Journal: Am J Hematol Date: 2016-09-03 Impact factor: 10.047
Authors: Philippe Solal-Céligny; Monica Bellei; Luigi Marcheselli; Emanuela Anna Pesce; Stefano Pileri; Peter McLaughlin; Stefano Luminari; Barbara Pro; Silvia Montoto; Andrés J M Ferreri; Eric Deconinck; Noël Milpied; Leo I Gordon; Massimo Federico Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544
Authors: Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat Journal: Blood Date: 2004-05-04 Impact factor: 22.113